Aurinia Pharmaceuticals (AUPH) vs Palvella Therapeutics (PVLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Palvella Therapeutics (PVLA) has outperformed Aurinia Pharmaceuticals (AUPH) over the past year, gaining 51.8% versus a loss of 6.3%. Over five years, AUPH leads with a -24.0% price change compared with -48.4% for PVLA. Palvella Therapeutics is the larger company by market cap ($2.09 billion vs $1.97 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUPH | PVLA |
|---|---|---|
| Share price | $14.70 | $142.85 |
| Market cap | $1.97B | $2.09B |
| 1-day change | -1.28% | -2.00% |
| YTD return | -7.84% | +36.48% |
| 1-year return | -6.25% | +51.82% |
| 5-year return | -23.95% | -48.39% |
| P/E ratio (TTM) | 6.45 | — |
| Forward P/E | 12.67 | — |
| EPS (TTM) | $2.28 | $-5.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $283.06M | — |
| Revenue growth (YoY) | +20.38% | — |
| Net income (latest FY) | $287.20M | $-41.72M |
| Gross margin | 88.46% | — |
| Operating margin | 37.06% | — |
| Net margin | 101.47% | — |
| 52-week high | $19.25 | $179.95 |
| 52-week low | $13.52 | $72.23 |
| Distance from 52-week high | -23.64% | -20.62% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +25.85% | +63.42% |
| Average volume | 858.74K | 240.41K |
| Shares outstanding | 134.00M | 14.62M |
| Employees | 128 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PVLA has outperformed AUPH by 58.1 percentage points over the past year.
About Aurinia Pharmaceuticals
AUPH stock →Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Palvella Therapeutics
PVLA stock →Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
AUPH vs PVLA FAQ
Which is bigger, Aurinia Pharmaceuticals or Palvella Therapeutics?
Palvella Therapeutics (PVLA) is larger, with a market capitalization of $2.09B compared with $1.97B for Aurinia Pharmaceuticals (AUPH).
Which stock has performed better over the past year, AUPH or PVLA?
PVLA returned +51.82% over the past 12 months, compared with -6.25% for AUPH (price return, excluding dividends). Past performance does not predict future results.
Are Aurinia Pharmaceuticals and Palvella Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.